Replies to post #139260 on Biotech Values

[DewDiligence]

Update on Gantenerumab for early AD:

http://finance.yahoo.com/news/morphosys-antibody-reaches-major-milestone-055200700.html

MorphoSys AG announced today that its partner Roche has expanded the ongoing SCarlet RoAD Phase 2 clinical trial of gantenerumab for prodromal (early) Alzheimer's disease to a potentially pivotal study. The trial size will be increased from 360 to 770 participants, and a favorable outcome to the trial could be used by Roche to support a marketing application for gantenerumab.